Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant

SAN JOSE, Calif.: SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta...

Click to view original post